Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giuliano Bettoni Guglielmetti has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • José Pontes Junior

    Urology Department, LIM/55 ‐ Laboratory of urology Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo São Paulo SP Brazil

    2 shared publications
  • Adalberto Andriolo Junior

    Department of Urology, Men's Health Centre, Hospital Brigadeiro, São Paulo, Brazil

    1 shared publication
  • Adriano Borba Couto

    Department of Urology, Men's Health Centre, Hospital Brigadeiro, São Paulo, Brazil

    1 shared publication
  • Alcides Mosconi Neto

    Department of Urology, Men's Health Centre, Hospital Brigadeiro, São Paulo, Brazil

    1 shared publication
  • Aline Albertini

    Department of Urology, Men's Health Centre, Hospital Brigadeiro, São Paulo, Brazil

    1 shared publication
  • Claudio Bovolenta Murta

    Urology Department Instituto do Câncer do Estado de São Paulo São Paulo Brazil

    1 shared publication

Latest Publications

  • Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial

    by Leonardo Cardili, Diogo Assed Bastos, Eder Nisi Ilario, Marina Alessandra Pereira, Giuliano Bettoni Guglielmetti, Maurício Cordeiro, José Pontes, Rafael Ferreira Coelho, William Carlos Nahas, Katia Ramos Moreira Leite

    Purpose High-risk localized prostate cancer (HRLPC) commonly progresses to metastatic disease after local treatment. Neoadjuvant androgen deprivation therapy (nADT) before radical prostatectomy (RP) has recently been suggested to improve early oncological outcomes in HRLPC. We aimed to perform an exploratory analysis of the pathological outcomes from a prospective trial testing nADT before RP. Methods Prospective, single-centered, phase II, randomized trial performed between October 2018 and July 2021. Random assignment (1:1) for nADT modalities: goserelin (10.8 mg) plus abiraterone acetate (1000 mg/d) plus prednisone (5 mg/d), with or without apalutamide (240 mg/d) for 12 weeks, followed by RP (within 30 days) and extended lymph node dissection. Baseline clinical and pathological variables were assessed in needle biopsies before nADT. Tumor regression was histologically evaluated in surgical specimens using the residual cancer burden index (RCB). Results Sixty-two patients reached the surgical phase. Good response (RCB ≤ 0.25 cm³) was achieved in 14 patients (22.5%). Overall stage migration rate between baseline status (MRI before nADT) and final status (after surgery) was 27.4%. Late stage detection (high tumor burden, perineural invasion) and altered PTEN/ERG immunostatus showed significant association with poor response in univariate analysis. Higher baseline tumor burden was the only independent factor related to poor response in multivariate analysis. Conclusions There are subgroups of patients, such as those with low baseline cancer burden and PTEN/ERG wild-type status, more likely to achieve good response with nADT. In the case of long term oncological benefit to be proven, nADT might be an additional therapeutic resource for these patients.


  • Effectiveness of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of the Needle Tip in Decreasing Infectious Complications After Transrectal Prostate Biopsy: A Randomized Controlled Trial

    by Jose Pontes-Junior, Tiago Magalhães Freire, Felipe Guimarães Pugliesi, Felipe Machado de Moura Costa, Vinicius Meneguette Gomes de Souza, Fabio Pescarmona Galucci, Aline Albertini, Adriano Borba Couto, Claudio Bovolenta Murta, Giuliano Betoni Guglielmetti, et al.

    Purpose: Prostate biopsy is mostly performed through the transrectal route worldwide and infectious complications (ICs) may occur in up to 7% of cases. Therefore, alternative strategies to decrease ICs are needed. Our aim was to evaluate the effectiveness of intrarectal povidone-iodine cleansing plus formalin disinfection of the needle tip in decreasing ICs after transrectal ultrasound guided prostate biopsy. Materials and Methods: We conducted a prospective, single-center, phase-III trial in patients undergoing TRUS-Bx randomized 1:1 to rectal mucosa cleansing with gauze soaked in 10% povidone-iodine solution wrapped around the gloved index finger and needle tip disinfection by immersion in a 10% formalin solution before each puncture versus control group. The primary endpoint was the rate of ICs defined as one or more of the following events: fever, urinary tract infection (UTI) or sepsis. Results: Overall, 633 patients were randomized to the intervention group and 623 to the control group. The IC rate was 3.9% in the intervention group and 6.4% in the control group (RR 0.61; 95% [CI] 0.36–0.99; p=0.049). The rates of sepsis, UTI, and fever were 0.3% vs. 0.5% (p=0.646), 2.3% vs. 4.1% (p=0.071), and 1.3% vs. 1.9% (p=0.443), respectively. The positive urine culture rate was 5.2% in the intervention group and 9% in the control group (RR 0.57; p=0.015). There was no statistically significant difference between the groups regarding the occurrence of non-infectious adverse events. Conclusions: Intrarectal povidone-iodine cleansing plus formalin disinfection of the biopsy needle tip was associated with a reduction in ICs after transrectal prostate biopsy.